1 Based on the mechanism of action, if the transduced cells cross the placenta, they may cause fetal toxicity, including B-cell lymphocytopenia.1 Therefore, tisagenlecleucel is not recommended for women who are pregnant, and pregnancy after tisagenlecleucel administration should be discussed ...
infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the MTD, patients received either 1 × 10(6) CAR-transduced T cells/kg (dose 1), 3 × 10(6) CAR-transduced T cells/kg (dose 2), or the entire CAR T cell product if sufficient numbers of ...
“While CAR-T cell therapies have revolutionized the way we treat multiple hematologic malignancies, the relapsed or refractory illness still impacts many patients with LBCL who are in need of additional treatment options. By advancing this Phase 1b study, we hope to pave the way ...
The kinetics of delayed CRS, characteristic of T cell and tumor cell interaction, have also been observed in patients receiving blinatumomab, a bispecific T cell-engaging antibody targeted to CD3/CD19. Although blinatumomab is not an adoptive cellular therapy, its mechanism of action depends on ...
“Acute lymphoblastic leukemia is the most common form of childhood cancer,” John said during the presentation. “This specific subtype, B-ALL, accounts for greater than 80% of cases. Although the majority of pediatric patients with B-ALL have excellent outcomes, approximately...